AKT1 and Miyoshi myopathy: Both hyperactivation of the PI3K/AKT/mTOR and JAK/STAT signaling pathways, for example, are associated with poor prognosis and MM tumor proliferation, and are actively being explored in preclinical drug research as potential drug targets [48,49].